AstraZeneca U.S. succession plan
Executive Summary
AstraZeneca Senior VP-U.S. Commercial Operations Tony Zook will replace U.S. President and Exec VP-North America David Brennan effective Jan. 1. Brennan has been named to succeed retiring CEO Tom McKillop (1"The Pink Sheet" Aug. 1, 2005, p. 11). Zook, who joined predecessor company Astra in 1997, previously served as AstraZeneca VP-sales; he has been leading U.S. commercial operations since Brennan was promoted to North America head in 2001 (2"The Pink Sheet" June 4, 2001, p. 32)...
You may also be interested in...
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO
AstraZeneca
Senior VP-U.S. Commercial Operations David Brennan will become Exec VP-North America following the retirement of C.G. Johansson in July. Brennan will be succeeded by VP-Sales Tony Zook
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.